LeadArtis participates in the second IACT update meeting as well as in the “Immunostimulatory monoclonal antibodies and immunomodulation: harvesting the crop“ international symposium

01-11-2015

The second IACT assessment meeting took place during November 20-21, 2015 in Pamplona, Spain. LeadArtis is a partner of the Immunostimulatory Agonist Antibodies for Cancer Therapy, a 6.9M€ funding consortium which incorporates long-standing expertise in agonist immunostimulatory antibodies (IS-Abs) from research institutions and small-medium enterprises (SEM) in five European countries (Germany, Italy, Spain, Sweden and United Kingdom).

The IACT project (FP7) website is up and running

07-09-2015

LeadArtis is a partner of the IACT (Immunostimulatory Agonist Antibodies for Cancer Therapy) 6.9M€ funding consortium (Project Number: 602262). The IACT is an interdisciplinary platform that involves a total of 10 partners with long-standing expertise in agonist immunostimulatory antibodies (IS-Abs), from research institutions and small-medium enterprises (SEM) located in five European countries (Germany, Italy, Spain, Sweden and United Kingdom).

Escherichia coli offers short-cut to large-scale Trimerbody® manufacturing

05-08-2015

Trimerbody® is a unique mono/multispecific antibody format based on the use of specific collagen trimerization domains and optimized peptide linkers. Trimerbodies are trimeric in solution and exhibit excellent antigen binding capacity and stability in vitro and in vivo.

LeadArtis participates in the first IACT scientific update meeting

15-01-2015

The first IACT review meeting took place on November 17-18, 2014 in Frankfurt, Germany. Representatives of all partners, including management and scientific teams participated in the assembly.

Leadartis announces its partnership in the TERET project.

28-10-2014

Leadartis is proud to announce its participation as a partner in the TERET project (New Treatments for Degenerative Retina Diseases) funded by the Spanish Ministry of Economy and Competitiveness (MINECO) under the RETOS of the society program. The MINECO’s participation demonstrates its support of Leadartis technology research and main objectives.

Leadartis reports its business strategy at BioSpain 2014

25-09-2014

Leadartis has participated in BioSpain 2014 recently held in Santiago de Compostela (November 24-26th). BioSpain was chosen to present our business to the sector since is the most important biotechnology event in Spain and one of the most important internationally.

Leadartis announces the appointment of Dr. Francisco Sanchez-Madrid as a member of its Scientific Advisory Board

04-09-2014

Madrid (September 4th, 2014). Leadartis, a privately held biotechnology company, is pleased to announce the appointment of Dr. Francisco Sanchez-Madrid as a member of its Scientific Advisory Board (SAB). Dr. Sanchez-Madrid together with the outstanding scientists and drug development professionals: Dr. L. Alvarez-Vallina, Dr. P. Kristensen, Dr. I. Melero and Dr. L.

Leadartis to present its business at BioSpain 2014 on September 24th, 2014

04-09-2014

Madrid (September 3rd). Leadartis, a privately held biotechnology company, is pleased to announce is participation at the BioSpain 2014 international biotechnology conference to be held in Santiago de Compostela (Spain) in September, 24th-26th, 2014

Leadartis reports an efficient method for production of Trimerbody® molecules in Pichia Pastoris

01-08-2014

In collaboration with prestigious academic institutions, LeadArtis´scientists demonstrated that single-chain fragment variable (scFv)-based N-terminal Trimerbody® molecules can be efficiently produced in the methylotrophic yeast Pichia pastoris (P. pastoris) in a trimeric fully functional active form. The yield of scFv-based N-terminal Trimerbody® molecules expressed in P. pastoris was about 20-fold higher than in mammalian cells. New marketed therapeutic proteins produced in Pichia evidence the rising interest of P.

Syndicate content

Latest News

SARS-CoV-2 Spike Trimerbody could represent a therapeutic option for COVID-19.
14-10-2021

We are glad to report that in a recently published EMBO Journal...

"Tumor-targeted costimulatory trimerbodies for cancer Immunotherapy”- A brief discussion with Juan Perez Villar, CEO, LEADARTIS.
07-06-2021

...

Diario ABC España y Cadena Cope: Investigadores crean un nuevo anticuerpo antitumoral más eficaz
01-06-2021

El director de la unidad de inmunoterapia del cáncer del Instituto de Investigación del Hospital...